US Patent 10442815 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Patent 10442815 was granted and assigned to Karus Therapeutics on October, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+64 characters)
Article
Patent abstract
The invention relates to a compound of formula I:
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 3 Oct, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Alexander R. L. Cecil0
Alice E. Gatland0
Daniel J. Finnemore0
Franck A. Silva0
Rikki P. Alexander0
Stephen J. Shuttleworth0
Edits on 26 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 27 Mar, 2023
Golden AI
Infobox
Edits on 25 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 26 Sep, 2022
Golden AI
Infobox
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
104428150
Date of Patent
October 15, 2019
0Patent Application Number
157533580
Date Filed
August 19, 2016
0Patent Citations
Patent Citations Received
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Edits on 3 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 29 Jan, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
US Patent 10442815 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10442815
Date of patent
October 15, 2019
Patent application number
15753358
Date Filed
August 19, 2016
Patent citations
Patent primary examiner
Find more entities like US Patent 10442815 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
